Cyteir Therapeutics, Inc.
News
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tol
Business Wire Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with...\n more…
Cyteir Therapeutics 10% Owner Trades $529K In Company Stock
Benzinga Novo Holdings AS, 10% Owner at Cyteir Therapeutics CYT, reported a large insider sell on July 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that AS sold 200,937 shares of Cyteir Therapeutics. The total transaction amounted to $529,288.\n more…
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
Business Wire Cyteir Therapeutics, Inc. (Cyteir or the Company) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and...\n more…
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
Business Wire Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in...\n more…
Wedbush Sticks to Its Buy Rating for Cyteir Therapeutics (CYT)
TipRanks Financial Blog In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Cyteir Therapeutics ( - Research Report), with a price target of $3.00. The company's shares opened today at $2.21. According to TipRanks, Driscoll is an analyst with an average return of -1.0% and a 34.64% success rate.\n more…
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
Business Wire Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights. We have made encouraging progress enrolling patients in the CYT-0851 Phase 1...\n more…